February 2, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Julie Sherman Kate Tillan Jason L. Drory Chris Edwards | |
| Re: | Pharvaris B.V. Registration Statement on Form F-1 (File No. 333-252157) Request for Acceleration of Effective Date | |
Dear Ladies and Gentlemen:
In connection with the proposed offering of the securities under the above-captioned Registration Statement on Form F-1 (the “Registration Statement”), we wish to advise you that we, as representatives of the underwriters, hereby join with Pharvaris B.V.’s request that the effective date of the Registration Statement be accelerated so that the same will become effective on February 4, 2021 at 2:00 p.m. E.S.T., or as soon as practicable thereafter.
Pursuant to Rule 460 under the Securities Act of 1933, please be advised that, as representatives of the underwriters, we have distributed approximately 2,449 copies of the preliminary prospectus, dated February 1, 2021, through the date hereof.
We, the undersigned, as representatives of the several underwriters, will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Signature Page Follows]
| Sincerely, | ||
| MORGAN STANLEY & CO. LLC BOFA SECURITIES, INC. SVB LEERINK LLC
As representatives of the Underwriters
MORGAN STANLEY & CO. LLC | ||
| By: | /s/ Kalli Dircks | |
| Name: Kalli Dircks | ||
| Title: Managing Director | ||
| BOFA SECURITIES, INC. | ||
| By: | /s/ Michael Liloia | |
| Name: Michael Liloia | ||
| Title: Director | ||
| SVB LEERINK LLC | ||
| By: | /s/ Gabriel Cavazos | |
| Name: Gabriel Cavazos | ||
| Title: Managing Director | ||
[Signature Page to UW Acceleration Request]